RT Journal Article
SR Electronic
T1 Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.05.20241927
DO 10.1101/2020.12.05.20241927
A1 SA Kemp
A1 DA Collier
A1 R Datir
A1 IATM Ferreira
A1 S Gayed
A1 A Jahun
A1 M Hosmillo
A1 C Rees-Spear
A1 P Mlcochova
A1 Ines Ushiro Lumb
A1 David J Roberts
A1 Anita Chandra
A1 N Temperton
A1 The CITIID-NIHR BioResource COVID-19 Collaboration
A1 The COVID-19 Genomics UK (COG-UK) Consortium
A1 K Sharrocks
A1 E Blane
A1 JAG Briggs
A1 MJ van Gils
A1 KGC Smith
A1 JR Bradley
A1 C Smith
A1 R Doffinger
A1 L Ceron-Gutierrez
A1 G Barcenas-Morales
A1 DD Pollock
A1 RA Goldstein
A1 A Smielewska
A1 JP Skittrall
A1 T Gouliouris
A1 IG Goodfellow
A1 E Gkrania-Klotsas
A1 CJR Illingworth
A1 LE McCoy
A1 RK Gupta
YR 2020
UL http://medrxiv.org/content/early/2020/12/29/2020.12.05.20241927.abstract
AB SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and ΔH69/ΔV70 in the S1 N-terminal domain NTD of the Spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype diminished in frequency, before returning during a final, unsuccessful course of convalescent plasma. In vitro, the Spike escape double mutant bearing ΔH69/ΔV70 and D796H conferred decreased sensitivity to convalescent plasma, whilst maintaining infectivity similar to wild type. D796H appeared to be the main contributor to decreased susceptibility, but incurred an infectivity defect. The ΔH69/ΔV70 single mutant had two-fold higher infectivity compared to wild type and appeared to compensate for the reduced infectivity of D796H. Consistent with the observed mutations being outside the RBD, monoclonal antibodies targeting the RBD were not impacted by either or both mutations, but a non RBD binding monoclonal antibody was less potent against ΔH69/ΔV70 and the double mutant. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy associated with emergence of viral variants with reduced susceptibility to neutralising antibodies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). SAK is supported by the Bill and Melinda Gates Foundation via PANGEA grant: OPP1175094. DAC is supported by a Wellcome Trust Clinical PhD Research Fellowship. CJRI acknowledges MRC funding (ref: MC_UU_00002/11). This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit (CCTU) and by the UCL Coronavirus Response Fund and made possible through generous donations from UCLs supporters alumni and friends (LEM). JAGB is supported by the Medical Research Council (MC_UP_1201/16).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee (17/EE/0025). The patient provided written informed consent. Additional controls with COVID19 were enrolled to the NIHR BioResource Centre Cambridge under ethics review board (17/EE/0025). Written consent to publish the report was obtained after death from the patients family.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLong-read sequencing data that support the findings of this study have been deposited in the NCBI SRA database with the accession codes SAMN16976824 - SAMN16976846 under BioProject PRJNA682013 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA682013). Short reads and data used to construct figures were deposited at https://github.com/Steven-Kemp/sequence_files.